A study from The BMJ indicates that the newest class of migraine drugs—which includes Pfizer’s Nurtec, AbbVie’s Ubrelvy and Eli Lilly’s Reyvow—is less effective in the acute treatment… read more.
Pain may be the most prevalent and severe symptom reported by individuals with long Covid, according to a new study led by UCL (University College London) researchers. The study,… read more.
Treatment for rheumatoid arthritis (RA) has come a long way in recent years. In many cases, a battery of medications can now successfully stymy the inflammatory cells that… read more.
In a study published in Nature Mental Health, scientists from China and the United States have found that individuals suffering from chronic musculoskeletal pain (CMP) may face a higher… read more.
Boston Scientific Corporation announced that the FDA has approved an expanded indication of the WaveWriter SCS Systems for the treatment of chronic low back and leg pain in… read more.
Sumitomo Pharma Canada, Inc. and Pfizer Canada announced that Health Canada has granted a Notice of Compliance (NOC) for Myfembree (Relugolix, estradiol and norethindrone acetate tablets) for the… read more.
In a recent randomized clinical trial of patients with fibromyalgia, cognitive-behavioral therapy (CBT)—which uses structured techniques to alter distorted thoughts and negative moods—was superior to a matched education… read more.
Medtronic plc has received CE (Conformité Européenne) Mark approval for its Inceptiv closed-loop rechargeable spinal cord stimulator (SCS). It is the first Medtronic SCS device to offer a… read more.
AbbVie announced that the European Commission has approved Aquipta (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month. The approval… read more.
Over the last 10 years, there has been a shift to fewer codeine prescriptions and an increase in prescriptions for stronger opioids, such as hydrocodone, hydromorphone and oxycodone… read more.
Patients with rheumatic and musculoskeletal conditions are vulnerable to long term opioid use, with up to 1 in 3 of those with rheumatoid arthritis or fibromyalgia, who take… read more.
Recruiting osteoarthritis patients with a lot of pain to clinical studies, may give incorrect results if the researcher does account for the natural variation in pain that occurs…. read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
